

=> d his

(FILE 'HOME' ENTERED AT 11:59:43 ON 03 MAY 2003)

FILE 'USPATFULL' ENTERED AT 12:00:51 ON 03 MAY 2003

L1 4 S SOMATOSTATIN(P)HYPERTENSION(P) (INSULIN)

FILE 'CAPLUS, EMBASE, MEDLINE' ENTERED AT 12:01:32 ON 03 MAY 2003

FILE 'CAPLUS, EMBASE, MEDLINE' ENTERED AT 12:01:38 ON 03 MAY 2003

L2 89 S SOMATOSTATIN(P)HYPERTENSION(P) (INSULIN)

L3 46 DUP REM L2 (43 DUPLICATES REMOVED)

FILE 'WPIDS' ENTERED AT 12:05:46 ON 03 MAY 2003

L4 17 S SOMATOSTATIN(P)HYPERTENSION

FILE 'USPATFULL' ENTERED AT 12:06:40 ON 03 MAY 2003

L5 11 S SOMATOSTATIN(P)HYPERTENSION

```
=> s (insulin resist?)(P)syndrome x(P)oct?
      28297 INSULIN
      1153827 RESIST?
      2418 INSULIN RESIST?
            (INSULIN(W)RESIST?)
      38092 SYNDROME
      811467 X
      432 SYNDROME X
            (SYNDROME(W)X)
      433610 OCT?
L4      0 (INSULIN RESIST?)(P)SYNDROME X(P)OCT?
```

```
=> d his
```

```
(FILE 'HOME' ENTERED AT 11:18:18 ON 03 MAY 2003)
```

```
FILE 'USPATFULL' ENTERED AT 11:18:34 ON 03 MAY 2003
```

```
L1      319 S INSULIN(P)SYNDROME X
L2      288 S (INSULIN RESIST?)(P)SYNDROME X
L3      1 S (INSULIN RESIST?)(P)SYNDROME X(P)SOMATO?
L4      0 S (INSULIN RESIST?)(P)SYNDROME X(P)OCT?
```

```
=> s 12
      28297 INSULIN
      1153827 RESIST?
      2418 INSULIN RESIST?
            (INSULIN(W)RESIST?)
      38092 SYNDROME
      811467 X
      432 SYNDROME X
            (SYNDROME(W)X)
L5      288 (INSULIN RESIST?)(P)SYNDROME X
```

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2

AN 1984:185956 CAPLUS

DN 100:185956

TI A super active cyclic hexapeptide analog of somatostatin

AU Veber, Daniel F.; Saperstein, Richard; Nutt, Ruth F.; Freidinger, Roger M.; Brady, Stephen F.; Curley, Paul; Perlow, Debra S.; Paleveda, William J.; Colton, C. Dylion; et al.

CS Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA

SO Life Sci. (1984), 34(14), 1371-8

CODEN: LIFSAK; ISSN: 0024-3205

DT Journal

LA English

AB Cyclo(N-methyl-**Ala-Tyr-D-Trp-**

Lys-Val-Phe) (I) [81377-02-8] was 50-100-fold more potent than cyclic somatostatin [38916-34-6] for the inhibition of insulin [9004-10-8], glucagon [9007-92-5] and growth hormone [9002-72-6] release as revealed by structure-**activity** studies of cyclic hexapeptide analogs of somatostatin in rats. The hydroxyl group of tyrosine conferred a 10-fold **enhancement** to the potency. Potency was also correlated with hydrophobicity. I improved the control of postprandial hyperglycemia in diabetic animals when given in combination with insulin. The analog was quite stable in the blood and in the gastrointestinal tract, but the bioavailability after oral administration was only 1-3%. The biol. properties and long duration of I should allow clin. evaluation of the inhibition of glucagon release as an adjunct to insulin in the treatment of patients with diabetes.